Barclays Initiates Coverage of Humacyte at Equal-Weight
Fintel reports that on October 7, 2026, Barclays initiated coverage of Humacyte (NASDAQGS:HUMA) with a Equal-Weight recommendation.
This initiation follows a prior action on April 8, 2026, when Barclays maintained an Overweight rating on the stock. Prior to the current rating action, the stock closed at $0.48 on October 6, 2026. Humacyte's share price has recently declined, showing a one-week price change of -10.27% from a baseline close of $0.53 on September 29, 2026, and a one-month price change of -20.98% from a baseline close of $0.60 on September 4, 2026.
In its latest financial results reported on August 12, 2026, Humacyte posted an actual EPS of -0.16, which was below the estimated EPS of -0.102. The company's actual revenue for the quarter was $406,000.00, falling short of the estimated revenue of $1,138,320.00. The company's upcoming earnings announcement is scheduled for November 6, 2026.
Separately from Barclays' individual rating, the broader analyst consensus shows a target mean of $1.89 and a target median of $1.28 as of October 2, 2026. This current mean target represents an implied change of +294.77% from recent trading levels. The consensus target mean has remained unchanged at $1.89 since September 15, 2026, reflecting a revision of 0.00%.
The aggregate analyst sentiment has also remained steady. For the current recommendation period beginning September 1, 2026, there are 11 total recommendations, including 3 strong buy, 6 buy, 2 hold, 0 sell, and 0 strong sell ratings. This breakdown translates to 81.8% positive, 18.2% hold, and 0.0% negative recommendations. These figures are identical to the prior recommendation period starting August 1, 2026, which also recorded 11 total recommendations with 3 strong buy, 6 buy, 2 hold, 0 sell, and 0 strong sell ratings.
Recent analyst actions
| Date | Analyst | Prior | Latest recommendation | Action |
|---|---|---|---|---|
| October 7, 2026 | Barclays | Equal-Weight | initiated coverage |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.